A diverse group of MASLD/MASH stakeholders joins Jörn Schattenberg and Roger Green to discuss The Liver Meeting 2024 about key breakthroughs, explore emerging research on new therapies, and reflect on collaborative efforts that advance patient care and outcomes in the field.
In the second half of Roger Green’s interview with Global Liver Institute Vice President, Liver Programs Jeff McIntyre, Jeff discusses the implications of his key EASL Congress takeaways for GLI and other patient advocacy groups.
Global Liver Institute Vice President of Liver Programs Jeff McIntyre joins Roger Green to discuss what he considers key takeaways for GLI from EASL Congress 2024.
PharmaNest Founder and CEO Mathieu Petitjean joins Roger Green to discuss key implications for his business from what he learned at EASL Congress 2024.
EASL Secretary General Aleksander Krag offers his vision for the EASL Congress 2024, after which Hannes Hagstrom shared some impressions.
MASLD patient advocates consider new needs and opportunities for other stakeholders after the Rezdiffra approval and launch.
This conversation focuses on what panelists believe to be the major lessons the BioPharma industry should take from Madrigal’s success in bring Rezdiffra to launch.
Last Thursday, FDA approved Rezdiffra, the first MASH drug! A global panel of key opinion leaders joins the Surfers to share excitement and discuss the implications of this landmark event.
Maru Rinella, Jeff Lazarus and Meena Bansal, all key players in the new MASLD nomenclature process join patient advocate Mike Betel, Louise Campbell and Roger Green to discuss the process, the benefits of the outcome, and where things go from here.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to discuss the role that MASLD patient advocates and others are likely to play in MASH drug access decisions, along with education and informational processes.
